No­var­tis to shut­ter NC-based San­doz plant ahead of spin­off

3 years ago
Manufacturing

Dig­i­tal re­call? On­col­o­gists see dozens of on­line ads every month but on­ly re­mem­ber a hand­ful — study

3 years ago
Pharma
Marketing

HHS lines up near­ly $700M in sup­ply deals to com­bat mon­key­pox and stock up on a small­pox treat­ment

3 years ago
Pharma
Manufacturing

Pfiz­er buys in­to de­cen­tral­ized co­op­er­a­tive to ac­cel­er­ate R&D in hu­man longevi­ty

3 years ago
Deals

Four years and $145M+ lat­er, No­vo Nordisk hands back the rights to hor­mone growth de­fi­cien­cy test

3 years ago
R&D

Af­ter clin­i­cal hold quashed its hopes, Yu­man­i­ty field­ed 10 bid­ders be­fore land­ing on two-way deal with J&J, Kine­ta

3 years ago
Deals

Covid-19 roundup: Mod­er­na gets Swiss boost­er OK; Bi­va­lent shots ex­pect US EUA sans com­plete in-hu­man da­ta — re­port

3 years ago
Coronavirus

David Bak­er’s lab and ARCH sprout Lord of the Rings-in­spired macro­cy­cle biotech

3 years ago
Financing

As­traZeneca’s Pas­cal So­ri­ot says Covid-19 boost­ers may not be for every­one — re­port

3 years ago
Coronavirus

As Hori­zon works to beef up drug sales, CEO Wal­bert maps a big man­u­fac­tur­ing ex­pan­sion in Ire­land, 350 new jobs

3 years ago
Manufacturing

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

3 years ago
R&D
In Focus

#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

3 years ago
R&D
Pharma

#ESC22: Cin­Cor CMO’s 17-year jour­ney in bring­ing a new hy­per­ten­sion drug to mar­ket con­tin­ues

3 years ago
R&D

#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke ...

3 years ago
R&D
Pharma

#ESC22: Bay­er's fac­tor XIa in­hibitor miss­es ef­fi­ca­cy marks in 2 PhII stud­ies but com­pa­ny dives straight in­to PhI­II

3 years ago
R&D
Pharma

#ESC22: ‘Anx­ious for more ev­i­dence’: As­traZeneca touts DE­LIV­ER da­ta in bid to ex­pand Farx­i­ga’s heart fail­ure ...

3 years ago
R&D
Pharma

Mod­er­na goes on the patent of­fen­sive; Pablo Legor­re­ta dou­bles down; Is a biotech re­cov­ery on the way?; and more

3 years ago
Weekly

Gilead fights back against BMS Supreme Court pe­ti­tion in patent fight

3 years ago
Pharma
Law

Drug man­u­fac­tur­ers must sub­mit re­ports on qual­i­ty prob­lems to FDA. Al­most half of sites still don't, new re­port finds

3 years ago
FDA+
Manufacturing

In­cyte se­cures sec­ond FDA ap­proval for bile duct can­cer drug in mu­tat­ed can­cer type

3 years ago
Pharma
FDA+

With two new ex­pen­sive gene ther­a­py ap­provals, out­comes-based pric­ing deals grab the spot­light again

3 years ago
R&D
Pharma

No­var­tis turns to re­al metasta­t­ic breast can­cer pa­tient for ‘first gen­er­a­tion’ Kisqali TV ad

3 years ago
Pharma
Marketing

US and Chi­na de­vel­op frame­work for in­spec­tion of 200 US-list­ed com­pa­nies un­der threat of delist­ing

3 years ago
China
Pharma

Ab­b­Vie scores a key win in Alzheimer's drug patent suit

3 years ago
Law
First page Previous page 471472473474475476477 Next page Last page
A service from the Financial Times